Healthcare & Pharmaceuticalscategory US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug June 17, 2024 Reuters, the news and media division of Thomson Reuters, ...

The BioNTech SE ADR BNTX slid 2.69% to $112.51 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the ...

BioNTech (NASDAQ:BNTX) announced Tuesday that its mRNA-based cancer therapy BNT111, in combination with Regeneron’s ...

BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session.

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $171.00. John Newman has given his Buy ...

Pfizer Inc. and BioNTech SE said Friday that a Phase 3 trial of their COVID-19-influenza combination vaccine candidate met one of its two objectives. The trial’s two primary objectives were for ...

The Food and Drug Administration has greenlighted three updated vaccines — the Pfizer-BioNTech and Moderna shots, and now a third one from Novavax, which was just authorized by the FDA on Friday.

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The company’s shares opened today at $121.40. According to ...

The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...

Users on X reported the change early on Friday, noting that the Facebook app's logo on their mobile devices — typically a white F on a blue background — had changed to a blue F on a black ...

GDANSK, Aug 19 (Reuters) - BioNTech (22UAy.DE), opens new tab on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its ...

Germany’s BioNTech has said it has not received any takeover approaches after it began a high-profile coronavirus vaccine trial with Pfizer in Germany, following press reports over the weekend.